Small molecule · developed by PTC Therapeutics
Vatiquinone (PTC743, EPI-743) is an oral solution agent studied in Friedreich ataxia and Leigh syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05515536 | Phase 3 | Friedreich Ataxia | Active not recruiting | PTCT |
| NCT02352896 | Phase 2 | Leigh Syndrome | Completed | PTCT |
| NCT01728064 | Phase 2 | Friedreich's Ataxia | Completed | PTCT |
| NCT01721733 | Phase 2 | Leigh Syndrome | Completed | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Friedreich AtaxiaFriedreich's AtaxiaLeigh Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →